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The tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) induces release of arachidonic acid (AA) from HeLa 
cells with a maximum at 223 h. Subsequently the extracellular level of AA decreases. Cycloheximide (CH, 10e5 M) does 
not influence the release of AA, however, it causes the AA level to remain elevated. In the presence of TPA and CH 
(i) re-uptake of AA is not altered, (ii) re-incorporation of AA into phosphatidylinositol (and phosphatidylethanolamine) 
is largely increased, and (iii) the level of lysophosphatidylinositol is elevated. The latter two phenomena can be prevented 
by fluocinolone acetonide (10e8 M), i.e. by inhibition of phospholipase A, (PLA,). These data point to a continuously 
elevated PLA, activity in the presence of TPA and CH. The phorbol ester appears to induce a proteinaceous principle 
which diminishes PLA, activity. 
Tumor promoter; Phospholipid metabolism; Phospholipase A,; Arachidonic acid 
1. INTRODUCTION 
The tumor promoter TPA has been shown to 
cause numerous metabolic changes in various cells, 
particularly with regard to membrane constituents 
[1,2]. Besides stimulation of PC turnover [3-81, 
probably as a consequence of the activation of a 
PC-specific phospholipase C [9, lo], increased de- 
acylation of phospholipids by PLA2 has been 
observed [ 1 l-l 31 which yields AA. Metabolites 
formed from AA may be responsible for altera- 
tions in the genome [14-171. 
This study was performed in order to learn more 
about the ‘strategy’ of the tumor promoter TPA in 
influencing AA metabolism in HeLa cells. This cell 
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represents a suitable model system for the analysis 
of TPA-effected alterations of membrane 
metabolism [3,18,19]. Evidence is presented which 
indicates that, in response to TPA, AA release is 
turned on and off in a stepwise fashion. 
2. MATERIALS AND METHODS 
TPA was a gift from Professor E. Hecker (German Cancer 
Research Center). It was kept in acetone as a 5 x 10e3 M stock 
solution at - 70°C. Fluocinolone acetonide (FA), PGE2, phos- 
pholipids, 1,2-dioctanoylglycerol, AA (Sigma, Miinchen), CH 
(Serva, Heidelberg), bovine serum albumin (BSA, electro- 
phoretically pure; Biomol, Ilvesheim, FRG) were obtained from 
the sources quoted. [I-‘%Z]AA (2.2 MBq/pmol) as well as 
[1(3)-‘4C]glycerol (1.11 MBq/Fmol) were from Amersham 
Buchler (Braunschweig). 
Cloned HeLa cells were cultivated as monolayers as described 
[20]. For experiments 9 x lo5 cells were transferred to plastic 
Petri dishes (Falcon 3.5 cm diameter). Prelabeling with 
[l-‘%]AA (7.4 kBq/ml) was as described [21]. For analysis of 
lysophospholipids 6 x lo5 cells were cultured for 24 h prior to 
prelabeling with [l(3)-i4C]glycerol (74 kBq/ml) in 1.5 ml com- 
plete medium for another 18 h period. The radioactive medium 
was replaced by 2 ml fresh medium containing 10% calf serum, 
if not otherwise indicated, as well as the compounds to be 
assayed. For determining the reincorporation rate of AA after 
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induced AA release, unlabeled cells were challenged with the 
compounds to be tested. After the times indicated [I-“‘C]AA 
(7.4 kBq/ml) was added for 0.5-h periods. Analysis of lipids 
from the medium as well as from cells was performed as in 
[21,22]. Extraction of lysophospholipids was carried out with n- 
butanol [23]. Separation of lysophospholipids was performed 
by two-dimensional chromatography [24]. 
Radioactivity was determined by use of a Linear Analyzer 
(Berthold, Wildbad, FRG). Experiments were performed at 
least in duplicate with comparable results. Values given are 
means of 3 dishes f SD. 
3. RESULTS AND DISCUSSION 
HeLa cells were prelabeled with [14C]AA as 
described [21] and then treated with TPA under 
various conditions. TPA, over a wide range of 
concentrations [21], induced the release of AA 
from HeLa cells with a peak at 2-3 h (shown for 
lo-’ M TPA in fig.lA). The release of AA oc- 
curred in the absence as well as presence of 10m5 M 
CH (fig.lA); in the latter case it even increased. 
This concentration of CH is sufficient to inhibit 
the incorporation of [3H]leucine into trichloro- 
acetic acid-precipitable material of HeLa cells 
within less than 1 h for at least 6 h by approx. 
, , I I 
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90%. These data, therefore, suggest that the TPA- 
induced release of AA in HeLa cells does not re- 
quire de novo protein synthesis. Probably a PLA2 
becomes effective due to inactivation of an in- 
hibitor [25-271. The glucocorticoid fluocinolone 
acetonide (FA) at 10m8 M was capable of pre- 
venting the liberation of AA almost completely 
(fig. 1A). 
In the presence of various concentrations of 
TPA the level of released AA started to decrease 
by 2-3 h ([21]; shown for 10e8 M TPA in fig.lA) 
and reached control values by approx. 20 h [21]. In 
order to analyze whether this decrease was due to 
elevated uptake of AA by the cells or reduced 
liberation of AA, the following experiment was 
performed. HeLa cells were treated with lo-’ M 
TPA and pulsed at various times afterwards with 
radioactive AA for 30-min periods. HeLa cells in- 
corporate AA linearly for almost 1 h (the amount 
of unlabeled AA released due to the action of TPA 
appears to be negligible in terms of isotope dilu- 
tion). The data (fig.lB) demonstrate that the rate 
of incorporation of AA into cellular lipids was not 
significantly altered by pretreatment with TPA, 
r 
TIME (h) 
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Fig. 1. Influence of TPA on release (A) and incorporation (B) of AA by HeLa cells. (A) TPA-induced AA release and influence of 
CH. HeLa cells were prelabeled for 5 h with [l-‘4C]AA and pretreated with CH (10m5 M) or FA (10m8 M) before replacing the radioac- 
tive medium by fresh complete medium containing acetone/PBS (0), acetone/CH (1O-5 M) ( q ), TPA (lo-* M)/PBS (a), TPA 
(10-s M)/CH (10m5 M) (m), or TPA (lo-’ M)/FA (10e8 M) (v). At the indicated time points the medium was analyzed for AA. (B) 
AA incorporation into cellular lipids of TPA-treated HeLa cells and influence of CH. Unlabeled HeLa cells were treated at zero time 
with acetone/PBS (1), acetone/CH (10m5 M) (2), TPA (lo-* M)/PBS (3), or TPA (lo-’ M)/CH (10m5 M) (4). After 1, 2 or 3 h 
[l-‘4C]AA was added for 30 min. Radioactivity in cellular lipid extracts was determined by liquid scintillation counting. 
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and certainly not stimulated. Therefore, a decrease 
of the extracellular AA level 2-3 h after addition 
of TPA appeared to be the result of reduction of 
AA release. 
The decrease in extracellular AA level beyond 
2-3 h may have different causes. By that time ap- 
preciable amounts of AA become metabolized and 
are released into the medium as prostaglandins 
(fig.2A and [21]) and to a smaller extent as HETE 
products (not shown). The appearance of AA 
metabolites in the medium accounted only partly 
for the decrease in AA level therein beyond 2-3 h 
after TPA addition. The metabolism of AA is 
largely prevented by CH (fig.2A), thus indicating 
that it requires de novo protein synthesis. Under 
these circumstances the AA level in the medium of 
TPA-treated cultures continues to stay elevated 
beyond 2-3 h (fig.lA). 
The AA metabolites missing in the presence of 
CH did not account for the total increase of AA in 
the medium. In the presence of CH the TPA- 
effected activation of PLA2 appeared to last longer 
than in its absence, i.e. CH appeared to prevent a 
decrease of PLA2 activity. CH, therefore, may in- 
terfere with the TPA-induced de novo synthesis of 
a PLAz-diminishing principle, either of an in- 
12 -r 
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hibitor [25-271 or of a modulating enzyme (e.g. a 
protease). 
Evidence in support of elevated PLAz activity in 
the presence of TPA plus CH is provided by in- 
vestigation of the incorporation of AA into phos- 
pholipids. On addition of radioactive AA to cells 
pretreated with TPA, increased labeling of PI and 
PE (not of PS and PC) was observed (fig.3A,B) 
which may indicate that these are the phospho- 
lipids previously deacylated [28]. This idea is sup- 
ported by the observation that on inhibition of 
TPA-effected AA release by FA, no increase in 
AA incorporation into these phospholipids oc- 
curred (fig.3B), i.e. they were probably not 
deacylated to such a degree and therefore less 
available as substrates for reacylation. Under these 
circumstances FA prevented AA release (fig.lA) 
but did not influence the rate of AA uptake (not 
shown). The further increase of AA incorporation 
in the presence of TPA plus CH (fig.3A) would ap- 
pear to indicate that even more substrate, par- 
ticularly lyso-PI, was generated. This is indeed the 
case for lyso-PI as shown in fig.3B (inset) but not 
for lyso-PC (not shown). The incorporation of AA 
into PI, which is usually l/3 of that of PC, almost 
approaches the PC level in the presence of TPA 
1 2 3 4 5 6 
WE 0 
Fig.2. PGE2 accumulation in the culture medium of HeLa cells under the influence of CH (A) and in the absence of serum (B). (A) 
At zero time prelabeled HeLa cells were treated with acetone/PBS (0), acetone/CH (10-j M) (O), TPA (lo-’ M/PBS (0) or TPA 
(IO-’ M)/CH (10e5 M) (m), and the medium was analyzed for PGEz. (B) The medium of prelabeled cells was replaced by fresh medium 
with (O,O) or without (Cl,=) 10% calf serum, and acetone (0,O) or TPA (3 X lo-’ M) (0,m) was added. At the indicated time 
points, the medium was analyzed for PGE2. 
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Fig.3. AA incorporation into cellular lipids of TPA-stimulated HeLa cells after treatment with CH (A) and FA (B). (A) Unlabeled 
HeLa cells were treated at zero time with acetone/PBS (l), acetone/CH (1O-5 M) (2), TPA (lo-* M)/PBS (3), or TPA (10m8 M/CH 
(10e5 M) (4). After 2 h [I-‘%]AA was added for 30 min. The distribution of radioactive AA in the phospholipids was analyzed. (B) 
At zero time HeLa cells were treated with acetone (l), FA (lo-’ M) (2), TPA (3 x lo-’ M) (3), or TPA (3 X lo-* M)/FA (lo-’ M) 
(4) for 2 h. Then [I-‘%Z]AA was added for 30 min and the labeling of phospholipids was analyzed. (Inset) For analysis of lysophospho- 
lipids cells were prelabeled for 18 h with [l(3)-%]glycerol and treated with acetone (l), TPA (lo-’ M) (2), TPA (lo-* M)/CH 
(10e5 M) (3), or TPA (lo-’ M)/FA (lo-’ M) (4) for 2 h. Analysis of lysophospholipids was performed as described in section 2. 
CH (fig.3A). These data argue for a more active These data demonstrate that the cellular responses 
state of a PLAz where CH was present. were due to the action of TPA. 
Therefore, by the action of TPA the synthesis of 
a protein may become induced which decreases 
PLAz activity leading to decreased release of AA 
and as a consequence to a reduction of the AA 
level due to regular AA incorporation by the cells. 
In the presence of CH, however, the synthesis of 
this protein is prevented, thus allowing the PLAz 
to continue to liberate AA from cells leading to a 
plateau provided the release is balanced by the up- 
take. 
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